查詢結果分析
來源資料
相關文獻
- The Efficacy of Regular Inhaled Salmeterol Via Diskhaler in Chinese Asthmatics
- Airway Hyperreactivity Modulated by Immunotherapy with Denatured Ovalbumin in Ovalbumin-Sensitized Guinea Pigs
- 過敏性氣喘
- 麻杏甘石湯對塵蟍誘發氣喘天竺鼠之影響
- 各年齡層氣喘病人食物過敏率與過敏程度之研究
- The Anti-Inflammatory Effect of a Long-Acting Theophylline (Unidur) in Patients with Bronchial Asthma
- 腎氣丸對塵蟍激發喘天竺鼠呼吸道發炎與免疫之影響
- 如何改善老年人氣喘病的療效
- 小兒氣喘處置之最新發展
- 氣喘的另類治療
頁籤選單縮合
題 名 | The Efficacy of Regular Inhaled Salmeterol Via Diskhaler in Chinese Asthmatics=以雙盲試驗來評估Salmeterol於氣喘病患的效果 |
---|---|
作 者 | 陳昌文; 薛尊仁; 張漢煜; 李政宏; | 書刊名 | 胸腔醫學 |
卷 期 | 12:3 1997.09[民86.09] |
頁 次 | 頁105-112 |
分類號 | 415.425 |
關鍵詞 | 氣喘; 最高吐氣流速; Bronchial asthma; Salmeterol; Peak expiratory flow rate; |
語 文 | 英文(English) |
中文摘要 | Salmeterol是一種新的長效吸入型β�神�抗劑,近年來開始使用於歐美。國外的 研究報告多肯定Salmeterol於氣喘病人氣管擴張及症狀治療的療效,但尚未有於華人氣喘 病患使用Salmeterol的經驗。本篇研究嘗試用Salmeterol 50微克每天兩次和安慰劑每天兩 次,雙盲且平行的治療方式來評估Salmeterol於華人氣喘病患者的療效。 六十四位成人氣喘病患符合篩選標準者,隨機將之分Salmeterol或安慰劑組。使用 Salmeterol或安慰劑前一星期列為基礎期,爾後有四個星期使用Salmeterol或安慰劑的治 療期,暨兩星期的追蹤期。病人除了原先之藥劑外,Salmeterol組同時接受Salmeterol 50 微克每天兩次經diskhaler之吸入治療,安慰組則接受經diskhaler每天兩次安慰劑的吸入 治療。其間每天要記錄病人的最高吐氣流速,肺功能,使用短效β�神�抗劑的次數,及早 晚的症狀指數。 我們的結果顯示,使用Salmeterol和使用安慰劑兩組病患於使用前的基本資料如年齡 、性別、身高、體重、用藥、FEV�窗BFVC均無顯著差異。使用Salmeterol的病人於使用期 間的FEV�窗BFVC、早晚最高吐氣流速較使用安慰劑的病人有顯著的增加。使用Salmeterol 的病人每天使用短效吸入型β�神�抗劑的次數也較使用安慰劑的病人顯著的減少。不過於 試驗期間,使用Salmeterol的病人較使用安慰劑的病人白天或晚上症狀指數的中間值並無 顯著的差異。 總之,我們的研究顯示Salmeterol每天兩次經diskhaler吸入使用可以明顯的改善氣喘 病患的肺功能,而且可以降低氣喘病患使用短效吸入型β�神�抗劑的次數。 |
英文摘要 | Salmeterol is a novel long-acting β��--agonist which has recently been used in Europe and North America. It is claimed that salmeterol is effective in both prolongation of bronchodilatation and symptom control in asthmatics. Its experience in Taiwan has not been reported yet. This study tried to assess the efficacy of salmeterol in Chinese asthmatics using a double-blind, placebo- control, and parallel-group protocol. Sixty-four adult asthmatic patients who fulfilled the inclusion criteria were randomizedly divided into salmeterol and placebo groups. There were two 1-week run-in period, a 4-week treatment period, and a 2-week follow-up period. Salmeterol group received regular use of Salmeterol 50 μg bid via diskhaler in addition to the previous medication during the treatment period, and placebo group received placebo via diskhaler. During the study period, both groups of patients received pulmonary function measurement and recorded the day-time and night-time symptom score, the daily peak expiratory flow rate, and the number of puffs of the rescue β��--agonist used daily. Our results showed that there were no difference in the age, sex, body weight, body height, medication, initial FEV�� and FVC between salmeterol and Placebo groups at the run-in period. In comparison to the placebo group, patients receiving salmeterol had a significantly greater increase in FEV1, FVC, morning and evening peak expiratory flow rate. The number of puffs of rescue β��--agonist used daily was significantly decreased in the salmeterol group compared to the placebo group. However, the median day-time and night-time symptom scores were not different between the salmeterol and placebo groups. In conclusion, adding of regular use of Salmeterol 50 μg bid via diskhaler in treatment of asthmatics could improve the pulmonary function and decrease the frequency of use of the rescue β��--agonist. |
本系統中英文摘要資訊取自各篇刊載內容。